Article
Radiology, Nuclear Medicine & Medical Imaging
A. L. Tam, V Papadimitrakopoulou, I. I. Wistuba, J. J. Lee, J. E. Ensor, E. S. Kim, N. Kalhor, G. R. Blumenschein, A. S. Tsao, J. Heymach, R. S. Herbst, M. E. Hicks, W. K. Hong, S. Gupta
Summary: The multidisciplinary approach, with a focus on the interventional radiologist's role in supporting the BATTLE and BATTLE-2 trials, was effective in optimizing lesion selection and improving the quality of biomarker analysis in lung cancer clinical trials.
CLINICAL RADIOLOGY
(2021)
Article
Oncology
Adam H. Fox, Mizuki Nishino, Raymond U. Osarogiagbon, M. Patricia Rivera, Lauren S. Rosenthal, Robert A. Smith, Farhood Farjah, Lynette M. Sholl, Gerard A. Silvestri, Bruce E. Johnson
Summary: Advances in biomarker-driven therapies for NSCLC offer opportunities to improve patient outcomes, but also pose challenges for equitable care delivery. Multidisciplinary teams face the challenge of completing comprehensive and timely biomarker testing and navigating the evolving evidence base for this complex and time-sensitive disease.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Review
Immunology
Jinghan Yang, Liang Qiu, Xi Wang, Xi Chen, Pingdong Cao, Zhe Yang, Qiang Wen
Summary: Immune checkpoint inhibitors have shown promise in breast cancer treatment, but current methods of detecting PD-L1 expression are limited. Developing new predictive biomarkers is crucial for improving patient selection for immunotherapy. Liquid biopsy can provide additional value in identifying patients who are likely to benefit from immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Niklas Kluemper, Jonas Saal, Fiamma Berner, Christa Lichtensteiger, Nina Wyss, Annkristin Heine, Franz Georg Bauernfeind, Joerg Ellinger, Peter Brossart, Stefan Diem, Sabine Schmid, Markus Joerger, Martin Frueh, Manuel Ritter, Michael Hoelzel, Lukas Flatz, Tobias Bald
Summary: Early dynamics of C reactive protein (CRP) can serve as a predictive biomarker for response to anti-PD-1 immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC). CRP flare-responders can predict ICB response and survival as early as 4 weeks after therapy initiation. Early CRP kinetics have no predictive value for chemoimmunotherapy or when steroids are administered concurrently.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Health Care Sciences & Services
Julie C. Lauffenburger, Thomas Isaac, Lorenzo Trippa, Punam Keller, Ted Robertson, Robert J. Glynn, Thomas D. Sequist, Dae H. Kim, Constance P. Fontanet, Edward W. B. Castonguay, Nancy Haff, Renee A. Barlev, Mufaddal Mahesri, Chandrashekar Gopalakrishnan, Niteesh K. Choudhry
Summary: Efforts to reduce inappropriate prescribing of high-risk medications to older adults have had limited success. This study aims to determine whether designing EHR tools using behavioral science principles can effectively reduce inappropriate prescribing and improve clinical outcomes in older adults. The NUDGE-EHR project utilizes a two-stage, 16-arm adaptive randomized pragmatic trial to identify the most effective EHR tool among primary care providers and their patients aged 65 years and older.
IMPLEMENTATION SCIENCE
(2021)
Review
Medicine, Research & Experimental
Kanghong Xu, Chengpeng Zhang, Tiantian Du, Abakundana Nsenga Ariston Gabriel, Xue Wang, Xiaomeng Li, Li Sun, Nan Wang, Xinquan Jiang, Yi Zhang
Summary: Lung cancer has the highest incidence and mortality rates worldwide, lacking early diagnostic biomarkers. Exosomes, as a mode of intercellular communication, play a role in regulating physiological processes in lung cancer by delivering various biomolecules. Studying the role of exosomes in diagnosing and treating lung cancer is crucial for improving treatment outcomes.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Oncology
Christine E. Edmonds, Sophia R. O'Brien, David A. Mankoff, Austin R. Pantel
Summary: The goals of precision oncology are to provide targeted drug therapy based on individual's tumor biology and enable prediction and early assessment of treatment response. Molecular imaging, specifically PET, has the potential to revolutionize clinical oncology, including breast oncology. This article reviews PET imaging biomarkers for early response assessment and predicting treatment outcomes in breast cancer.
Article
Respiratory System
Dhairya A. Lakhani, Sheau-Chiann Chen, Sanja Antic, Anel Muterspaugh, Christine Cook, Nancy Liu, Hina Shujat, Sophie Jouan, Brandon Winston, Kim Fields, Janelle Wenstrup, Sara L. Block, Amy Hinton, Alexandra Miller, Sarah Atmajoana, John T. Helton, Khushbu Patel, Aneri B. Balar, Katrina Brewer, Subodh Nag, Rajbir Singh, Anthony Disher, Luis Huerta, Richard Fremont, Otis Rickman, Heidi Chen, Rosana Eisenberg, Kim L. Sandler, Alexis Paulson, Ronald C. Walker, Chirayu Shah, Gary T. Smith, Bennett Landman, Stephen Deppen, Eric L. Grogan, Melinda C. Aldrich, Pierre P. Massion
Summary: A prospective longitudinal cohort study was established to build a biorepository of carefully annotated biological specimens and LDCT chest images for early detection of lung cancer. Participants aged 55-80 with a 5-year estimated risk of developing lung cancer were recruited from three institutions. To date, 480 participants have been enrolled and 19 lung cancers have been identified. This unique repository will allow for the derivation and validation of clinical, imaging, and molecular biomarkers for diagnosing lung cancer.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2021)
Article
Oncology
Omer An, Yangyang Song, Xinyu Ke, Jimmy Bok-Yan So, Raghav Sundar, Henry Yang, Sun Young Rha, Ming Hui Lee, Su Ting Tay, Xuewen Ong, Angie Lay Keng Tan, Matthew Chau Hsien Ng, Erwin Tantoso, Leilei Chen, Patrick Tan, Wei Peng Yong
Summary: This study introduces a novel A-to-I RNA editing signature as a prognostic and predictive biomarker in advanced gastric cancer, offering a new tool for improved patient stratification and response to therapy.
Review
Endocrinology & Metabolism
Philip Sutera, Matthew P. Deek, Kim Van Der Eecken, Alexander W. Wyatt, Amar U. Kishan, Jason K. Molitoris, Matthew J. Ferris, M. Minhaj Siddiqui, Zaker Rana, Mark V. Mishra, Young Kwok, Elai Davicioni, Daniel E. Spratt, Piet Ost, Felix Y. Feng, Phuoc T. Tran
Summary: Traditional clinical, histopathological, and radiographic features are insufficient to capture the heterogeneity of cancer patients, but genomic sequencing can personalize cancer treatment and play a crucial role in radiotherapy and adjunctive therapies.
Article
Immunology
Dejing Huang, Enyu Tang, Tianze Zhang, Guangquan Xu
Summary: Fatty acid metabolism plays a significant role in the pathogenesis, progression, and immune regulation of LUAD. By establishing a risk model, we found that risk score and staging are independent prognostic factors for LUAD patients. The high-risk group had lower immune cell infiltration, was more sensitive to chemotherapeutic agents, and had a poorer survival prognosis. We also identified three target genes associated with survival prognosis that are closely associated with clinical symptoms and immune cells and may serve as potential targets for immune-targeted therapy in LUAD.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, Rosalyn Anne Juergens, Adrian Sacher, Andrea S. Fung, Paul Wheatley-Price, Scott A. Laurie, Benjamin Levy, Julie R. Brahmer, Archana Balan, Noushin Niknafs, Egor Avrutin, Liting Zhu, Mark Sausen, Penelope A. Bradbury, Jill O'Donnell-Tormey, Pierre Olivier Gaudreau, Keyue Ding, Janet Dancey
Summary: Circulating tumor DNA (ctDNA) is useful for capturing primary resistance to immunotherapy in lung cancer. The BR.36 trial demonstrates the correlation between ctDNA response and radiologic response, and identifies molecular response as a predictor of longer progression-free and overall survival.
Article
Medicine, General & Internal
Katerina-Vanessa Savva, Michal Kawka, Bhamini Vadhwana, Rahul Penumaka, Imogen Patton, Komal Khan, Claire Perrott, Saranya Das, Maxime Giot, Stella Mavroveli, George B. Hanna, Melody Zhifang Ni, Christopher J. Peters
Summary: This study aims to create a Biomarker Toolkit to bridge the gap between biomarker discovery and clinical use by identifying clinically promising biomarkers. A validated checklist of attributes linked with successful biomarker implementation was generated through mixed-methodology, including systematic literature search, interviews, and a Delphi survey. The toolkit can be used to detect biomarkers with the highest clinical potential and shape the design and execution of biomarker studies.
Review
Biochemistry & Molecular Biology
Karolina H. Czarnecka-Chrebelska, Debjita Mukherjee, Sofya V. Maryanchik, Magdalena Rudzinska-Radecka
Summary: Chronic obstructive pulmonary disease (COPD) is a widespread chronic disease with high morbidity and mortality rates globally. Although long-term smoking is a major risk factor, the molecular mechanisms of COPD are still unclear. Various factors such as inflammation, protein imbalance, oxidative stress, and genetic modifications are believed to play a role in the development of emphysema. Furthermore, COPD is a significant risk factor for lung cancer, and the chronic inflammation accompanying COPD may contribute to its progression. Recent research on the molecular analysis of COPD and lung cancer has provided new insights into their pathogenesis, diagnosis, and treatment.
Review
Biochemistry & Molecular Biology
Anne Sibille, Jean-Louis Corhay, Renaud Louis, Vincent Ninane, Guy Jerusalem, Bernard Duysinx
Summary: This review examines the biological properties of eosinophils in non-small cell lung cancer (NSCLC) and their roles in both tumor promotion and inhibition. The potential value of eosinophils as prognostic and predictive biomarkers is discussed, along with the need for stronger clinical data. Perspectives on clinical and translational research topics in this area are also provided.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
